Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Ovarian Research
Published in: Journal of Ovarian Research 1/2018

Open Access 01-12-2018 | Research

Characterization of stem cell and cancer stem cell populations in ovary and ovarian tumors

Authors: Seema C. Parte, Surinder K. Batra, Sham S. Kakar

Published in: Journal of Ovarian Research | Issue 1/2018

Login to get access

Abstract

Background

Ovarian cancer is a complicated malady associated with cancer stem cells (CSCs) contributing to 238,700 estimated new cases and 151,900 deaths per year, worldwide. CSCs comprise a tiny fraction of tumor-bulk responsible for cancer recurrence and eventual mortality. CSCs or tumor initiating cells are responsible for self-renewal, differentiation and proliferative potential, tumor initiation capability, its progression, drug resistance and metastatic spread. Although several biomarkers are implicated in these processes, their distribution within the ovary and association with single cell type has neither been established nor demonstrated across ovarian tumor developmental stages. Therefore, precise identification, thorough characterization and effective targeted destruction of dormant and highly proliferating potent CSC populations is an immediate need.

Results

In view of this, distribution of various CSC (ALDH1/2, C-KIT, CD133, CD24 and CD44) and cell proliferation (KI67) specific markers in the ovarian surface epithelium (OSE) and cortex regions in normal ovary, and benign, borderline and high grade metastatic ovarian tumors by immuno-histochemistry and confocal microscopy was studied. We further confirmed their expression by RT-PCR analysis. Co-expression analysis of stem cell (OCT4, SSEA4) and CSC (ALDH1/2, CD44 and LGR5) markers with proliferation marker (KI67) in HG tumors revealed dual positive proliferating stem and CSCs, few non-proliferating stem/CSC (SSEA4+/KI67− and ALDH1/2+/KI67−) and only KI67+ cells in cortex, signifying dynamic populations and interesting cellular hierarchy in cortex region. Smaller spherical (≤ 5 μm) and larger spindle/elliptical shaped (~ 10 μm) cell populations with high nucleo-cytoplasmic ratio were detected across all samples (including normal ovaries) but with variable distribution and characteristic stage-wise marker expression across different tumor stages.

Conclusions

Diverse stem and CSC populations expressing characteristic markers revealing distinct phenotypes (spherical ≤5 μm and spindle/elliptical ~ 10 μm) were distributed within different tumor stages studied signifying dynamic and probable functional hierarchy within these cell types. Involvement of extra-ovarian sites of origin of stem and CSCs requires rigorous evaluation. Quantitative analysis of potent CSC populations, their mechanisms and pathways for self-renewal, chemo-resistance, metastatic spread etc. with respect to various markers studied, will provide better insights and targets for developing effective therapeutics to prevent metastasis and eventually help improve patient mortality.
Appendix
Available only for authorised users
Literature
1.
Chen WC, Qiu JT, Lai CH, et al. Outcomes and prognoses of patients with ovarian cancer using bevacizumab: 6-year experience in a tertiary care hospital of northern Taiwan. PLoS One. 2017;12(5):e0175703.CrossRefPubMedPubMedCentral
2.
Bapat SA, Mali AM, Koppikar CB, Kurrey NK. Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian Cancer. Cancer Res. 2005;65(8):3025–9.CrossRefPubMed
3.
Latifi A, Luwor RB, Bilandzic M, Nazaretian S, Stenvers K, Pyman J, Zhu H, Thompson EW, Quinn MA, Findlay JK, Ahmed N. Isolation and characterization of tumor cells from the ascites of ovarian Cancer patients: molecular phenotype of Chemoresistant ovarian tumors. PLoS One. 2012;7(10):e46858.CrossRefPubMedPubMedCentral
4.
Kakar SS, Ratajczak MZ, Powell KS, Moghadamfalahi M, Miller DM, Batra SK, Singh SK. Withaferin a alone and in combination with cisplatin suppresses growth and metastasis of ovarian Cancer by targeting putative Cancer stem cells. PLoS One. 2014;9(9):e107596.CrossRefPubMedPubMedCentral
5.
Foster R, Buckanovich RJ, Rueda BR. Ovarian cancer stem cells: working towards the root of stemness. Cancer Letts. 2013;338:147–57.CrossRef
6.
Garson K, Vanderhyden BC. Epithelial ovarian cancer stem cells: underlying complexity of a simple paradigm. Reproduction. 2014;149(2):R59–70.CrossRefPubMed
7.
Tysnes BB. Tumor-initiating and -propagating cells: cells that we would like to identify and control. Neoplasia (New York, NY). 2010;12(7):506–15.CrossRef
8.
9.
Agliano A, Calvo A, Box C. The challenge of targeting cancer stem cells to halt metastasis. Semin Cancer Biol. 2017;44:25–42.CrossRefPubMed
10.
Parte SC, Smolenkov AS, Batra SK, Ratajczak MZ, Kakar SS. Ovarian Cancer stem cells: unravelling a germline connection. Stem Cells Dev. 2017;26(24):1781–803.CrossRefPubMed
11.
Wilczynski SP, Chen Y, Chen W, Howell SB, Shively JE, Alberts S. Expression and mutational analysis of tyrosine kinase receptors c-kit, PDGFRα, and PDGFRβ in ovarian cancers. Hum Pathol. 2005;36(3):242–9.CrossRefPubMed
12.
13.
Conic I, Stanojevic Z, Velickovic LJ, Stojnev S, Petrovic AR, Krstic M, Stanojevic M, Bogdanović D, Stefanovic V. Epithelial ovarian cancer with CD117 phenotype is highly aggressive and resistant to chemotherapy. J Obstet Gynaecol Res. 2015;41(10):1630–7.CrossRefPubMed
14.
Huang R, Wu D, Yuan Y, Li X, Holm R, Trope CG, Nesland JM, Suo Z. CD117 expression in fibroblasts-like stromal cells indicates unfavorable clinical outcomes in ovarian carcinoma patients. PLoS One. 2014;9(11):e112209.CrossRefPubMedPubMedCentral
15.
Parrott JA, Kim G, Skinner MK. Expression and action of kit ligand/stem cell factor in normal human and bovine ovarian surface epithelium and ovarian Cancer. Biol Reprod. 2000;62:1600–9.CrossRefPubMed
16.
Silva IA, Bai S, McLean K, Yang K, Griffith K, Thomas D, Ginestier C, Johnston C, Kueck A, Reynolds RK, Wicha MS, Buckanovich RJ. Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival. Can Res. 2011;71(11):3991–4001.CrossRef
17.
Chen X, Zhang J, Zhang Z, Li H, Cheng W, Liu J. Cancer stem cells, epithelial-mesenchymal transition, and drug resistance in high-grade ovarian serous carcinoma. Hum Pathol. 2013;44(11):2373–84.CrossRefPubMedPubMedCentral
18.
Ffrench B, Gasch C, O’Leary JJ, Gallagher MF. Developing ovarian cancer stem cell models: laying the pipeline from discovery to clinical intervention. Mol Cancer. 2014;13:262.CrossRefPubMedPubMedCentral
19.
Cioffi M, D’Alterio C, Camerlingo R, Tirino V, Consales C, Riccio A, Ieranò C, Cecere SC, Losito NS, Greggi S, Pignata S, Pirozzi G, Scala S. Identification of a distinct population of CD133 CXCR4 cancer stem cells in ovarian cancer. Sci Rep. 2015;5:10357.CrossRefPubMedPubMedCentral
20.
Ricci F, Bernasconi S, Porcu L, Erba E, Panini N, Fruscio R, Damia G. ALDH enzymatic activity and CD133 positivity and response to chemotherapy in ovarian cancer patients. Am J Cancer Res. 2013;3(2):221–9.PubMedPubMedCentral
21.
22.
23.
24.
Gao M, Choi Y, Kang S, Youn JH, Cho N. CD24 cells from hierarchically organized ovarian cancer are enriched in cancer stem cells. Oncogene. 2010;29(18):2672–80.CrossRefPubMed
25.
Kristiansen G, Denkert C, Schlüns K, Dahl E, Pilarsky C, Hauptmann S. CD24 is expressed in ovarian Cancer and is a new independent prognostic marker of patient survival. Am J Pathol. 2002;161(4):1215–21.CrossRefPubMedPubMedCentral
26.
Nakamura K, Terai Y, Tanabe A, Ono YJ, Hayashi M, Maeda K, Ohmichi M, et al. CD24 expression is a marker for predicting clinical outcome and regulates the epithelial-mesenchymal transition in ovarian cancer via both the Akt and ERK pathways. Oncol Rep. 2017;37(6):3189–200.CrossRefPubMedPubMedCentral
27.
Korkolopoulou P, Lazaris A, Konstantinidou AE, Kavantzas N, Patsouris E, Christodoulou P, Thomas-Tsagli E, Davaris P. Differential expression of bcl-2 family proteins in bladder carcinomas. Relationship with apoptotic rate and survival. Eur Urol. 2002;41(3):274–83.CrossRefPubMed
28.
Page CL, Huntsman DG, Provencher DM, Mes-Masson A. Predictive and prognostic protein biomarkers in epithelial ovarian Cancer: recommendation for future studies. Cancers. 2010;2(2):913–54.CrossRefPubMedPubMedCentral
29.
Giurgea LN, Ungureanu C, Mihailovici MS. The immunohistochemical expression of p53 and Ki67 in ovarian epithelial borderline tumors. Correlation with clinicopathological factors. Romanian J Morphol Embryol. 2012;53(4):967–73.
30.
Liu P, Sun Y, Du J, Hou X, Meng H. CD105/Ki67 Coexpression correlates with tumor progression and poor prognosis in epithelial ovarian Cancer. Int J Gynecol Cancer. 2012;22(4):586–92.CrossRefPubMed
31.
Battista MJ, Mantai N, Sicking I, Cotarelo C, Weyer V, Lebrecht A, Solbach C, Schmidt M. Ki-67 as an independent prognostic factor in an unselected cohort of patients with ovarian cancer: results of an explorative, retrospective study. Oncol Rep. 2014;31(5):2213–9.CrossRefPubMed
32.
Abubakar M, Orr N, Daley F, Coulson P, Ali HR, Blows F, Garcia-Closas M, et al. Prognostic value of automated KI67 scoring in breast cancer: a centralised evaluation of 8088 patients from 10 study groups. Breast Cancer Res. 2016;18(1):104.CrossRefPubMedPubMedCentral
33.
Grisham RN, Iyer G, Sala E, Zhou Q, Iasonos A, Delair D, Aghajanian C, et al. Bevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal Cancer. Int J Gynecol Cancer. 2014;24(6):1010–4.CrossRefPubMedPubMedCentral
34.
Ratajczak MZ, Ratajczak J, Suszynska M, Miller DM, Kucia M, Shin D. A novel view of the adult stem cell compartment from the perspective of a quiescent population of very small embryonic-like stem cells. Circ Res. 2017;120(1):166–78.CrossRefPubMedPubMedCentral
35.
Virant-Klun I, Zech N, Rožman P, Vogler A, Cvjetičanin B, Klemenc P, Meden-Vrtovec H, et al. Putative stem cells with an embryonic character isolated from the ovarian surface epithelium of women with no naturally present follicles and oocytes. Differentiation. 2008;76(8):843–56.CrossRefPubMed
36.
Parte S, Bhartiya D, Telang J, Daithankar V, Salvi V, Zaveri K, Hinduja I. Detection, characterization, and spontaneous differentiation in vitro of very small embryonic-like putative stem cells in adult mammalian ovary. Stem Cells Dev. 2011;20(8):1451–64.CrossRefPubMedPubMedCentral
37.
White YA, Woods DC, Takai Y, Ishihara O, Seki H, Tilly JL. Oocyte formation by mitotically active germ cells purified from ovaries of reproductive-age women. Nature Med. 2012;18(3):413–21.CrossRefPubMed
38.
Kakar SS, Parte S, Carter K, Joshua IG, Worth C, Rameshwar P, Ratajczak MZ. Withaferin A (WFA) inhibits tumor growth and metastasis by targeting ovarian cancer stem cells. Oncotarget. 2017;8(43):74494–505.CrossRefPubMedPubMedCentral
39.
Parte S, Bhartiya D, Patel H, Daithankar V, Chauhan A, Zaveri K, Hinduja I. Dynamics associated with spontaneous differentiation of ovarian stem cells in vitro. J Ovarian Research. 2014;7:25.CrossRef
40.
41.
Motta PM, Makabe S. Germ cells in the ovarian surface during fetal development in humans. A three-dimensional microanatomical study by scanning and transmission electron microscopy. J Submicrosc Cytol. 1986;18(2):271–90.PubMed
42.
43.
Auersperg N. The stem-cell profile of ovarian surface epithelium is reproduced in the oviductal fimbriae, with increased stem-cell marker density in distal parts of the fimbriae. Int J Gynecol Pathol. 2013;32(5):444–53.CrossRefPubMed
44.
Ahmed N, Abubaker K, Findlay J, Quinn M. Cancerous ovarian stem cells: obscure targets for therapy but relevant to chemoresistance. J Cell Biochem. 2013;114(1):21–34.CrossRefPubMed
45.
46.
Flesken-Nikitin A, Hwang C-I, Cheng C-Y, Michurina TV, Enikolopov G, Nikitin AY. Ovarian surface epithelium at the junction area contains cancer-prone stem cell niche. Nature. 2013;495(7440):241–5.CrossRefPubMedPubMedCentral
47.
Kenda-Suster N, Smrkol S, Virant-Klun I. Putative stem cells and epithelial-mesenchymal transition revealed in sections of ovarian tumor in patients with serous ovarian carcinoma using immunohistochemistry for vimentin and pluripotency-related markers. J Ovarian Research. 2017;10(1):11.CrossRef
48.
Virant-Klun I, Skutella T, Hren M, Gruden K, Cvjeticanin B, Vogler A, Sinkovec J. Isolation of small SSEA-4-positive putative stem cells from the ovarian surface epithelium of adult human ovaries by two different methods. Biomed Res Int. 2013;2013:690415.PubMedPubMedCentral
49.
Patel H, Bhartiya B, Parte S. Further characterization of adult sheep ovarian stem cells and their involvement in neo-oogenesis & Follicle Assembly. J Ovarian Res. 2018;11(1):3.CrossRefPubMedPubMedCentral
50.
Patel H, Bhartiya D, Parte S, Gunjal P, Yedurkar S, Bhatt M. Follicle stimulating hormone modulates ovarian stem cells through alternately spliced receptor variant FSH-R3. J Ovarian Res. 2013;6:52.CrossRefPubMedPubMedCentral
51.
Virant-Klun I, Stimpfel M. Novel population of small tumour-initiating stem cells in the ovaries of women with borderline ovarian cancer. Sci Rep. 2016;6:34730.CrossRefPubMedPubMedCentral
52.
Liu KC, Yo YT, Huang RL, et al. Ovarian cancer stem-like cells with induced translineage-differentiation capacity and are suppressed by alkaline phosphatase inhibitor. Oncotarget. 2013;4(12):2366–82.PubMedPubMedCentral
53.
Inoue M, Ogawa HO, Miyata M, Shiozaki H, Tanizawa O. Expression of E-cadherin in normal, benign, and malignant tissues of female genital organs. Am J Clin Pathol. 1992;98(1):76–80.CrossRefPubMed
54.
Saw YT, Yang J, Ng SK, Liu S, Singh S, Singh M, Welch WR, Tsuda H, Fong WP, Thompson D, Vasiliou V, Berkowitz RS, Ng SW. Characterization of aldehyde dehydrogenase isozymes in ovarian cancer tissues and sphere cultures. BMC Cancer. 2012;12:329.CrossRefPubMedPubMedCentral
55.
Patel SA, Ramkissoon SH, Bryan M, Pliner LF, Dontu G, Patel PS, Rameshwar P, et al. Delineation of breast cancer cell hierarchy identifies the subset responsible for dormancy. Sci Rep. 2012;2:906.CrossRefPubMedPubMedCentral
56.
Schwede M, Spentzos D, Bentink S, Hofmann O, Haibe-Kains B, Harrington D, Culhane AC, et al. Stem cell-like gene expression in ovarian Cancer predicts type II subtype and prognosis. PLoS One. 2013;8(3):e57799.CrossRefPubMedPubMedCentral
57.
Winterhoff BJ, Maile M, Mitra AK, Sebe A, Bazzaro M, Geller MA, Starr TK, et al. Single cell sequencing reveals heterogeneity within ovarian cancer epithelium and cancer associated stromal cells. Gynecol Oncol. 2017;144(3):598–606.CrossRefPubMedPubMedCentral
58.
Ahmed N, Greening D, Samardzija C, Escalona RM, Chen M, Findlay JK, Kannourakis G. Unique proteome signature of post-chemotherapy ovarian cancer ascites-derived tumor cells. Sci Rep. 2016;6:30061.CrossRefPubMedPubMedCentral
59.
Zhang R, Zhang P, Wang H, Hou D, Li W, Xiao G, Li C. Inhibitory effects of metformin at low concentration on epithelial–mesenchymal transition of CD44 CD117 ovarian cancer stem cells. Stem Cell Res Ther. 2015;6:262.CrossRefPubMedPubMedCentral
60.
Stemberger-Papić S, Vrdoljak-Mozetic D, Ostojić DV, Rubesa-Mihaljević R, Krigtofić I, Brncić-Fisher A, Kragević M, Eminović S. Expression of CD133 and CD117 in 64 serous ovarian Cancer cases. Coll Antropol. 2015;39(3):745–53.PubMed
61.
Chen J, Wang J, Chen D, et al. Evaluation of characteristics of CD44+CD117+ ovarian cancer stem cells in three dimensional basement membrane extract scaffold versus two dimensional monocultures. BMC Cell Biol. 2013;14:7.CrossRefPubMedPubMedCentral
62.
Qin Q, Sun Y, Fei M, Zhang J, Jia Y, Gu M, Xia R, Chen S, Deng A. Expression of putative stem marker nestin and CD133 in advanced serous ovarian cancer. Neoplasma. 2012;3(59):310–5.CrossRef
63.
64.
Skoda J, Hermanova M, Loja T, et al. Co-expression of Cancer stem cell markers corresponds to a pro-tumorigenic expression profile in pancreatic adenocarcinoma. PLoS One. 2016;11(7):e0159255.CrossRefPubMedPubMedCentral
65.
Durko L, Wlodarski W, Stasikowska-Kanicka O, et al. Expression and clinical significance of Cancer stem cell markers CD24, CD44, and CD133 in pancreatic ductal adenocarcinoma and chronic pancreatitis. Dis Markers. 2017;2017:9617615.PubMedPubMedCentral
66.
Paula AD, Marques O, Sampaio R, Rosa A, Garcia J, Rêma A, Lopes C, et al. Characterization of CD44 ALDH1 Ki-67– cells in non-malignant and neoplastic lesions of the breast. Anticancer Res. 2016;36(9):4629–38.CrossRef
67.
Kalantari E, Asgari M, Nikpanah S, Salarieh N, Lari MH, Madjd Z. Co-expression of putative Cancer stem cell markers CD44 and CD133 in prostate carcinomas. Pathol Oncol Res. 2017;23(4):793–802.CrossRefPubMed
68.
Ibrahim-Hashim A, Robertson-Tessi M, Enriquez-Navas PM, Damaghi M, Balagurunathan Y, Wojtkowiak JW, Gatenby RA, et al. Defining Cancer subpopulations by adaptive strategies rather than molecular properties provides novel insights into Intratumoral evolution. Cancer Res. 2017;77(9):2242–54.CrossRefPubMedPubMedCentral
Metadata
Title
Characterization of stem cell and cancer stem cell populations in ovary and ovarian tumors
Authors
Seema C. Parte
Surinder K. Batra
Sham S. Kakar
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Journal of Ovarian Research / Issue 1/2018
Electronic ISSN: 1757-2215
DOI
https://doi.org/10.1186/s13048-018-0439-3

Other articles of this Issue 1/2018

Journal of Ovarian Research 1/2018 Go to the issue

Case report

Precise preoperative diagnosis of struma ovarii with pseudo-Meigs’ syndrome mimicking ovarian cancer with the combination of 131I scintigraphy and 18F–FDG PET: case report and review of the literature

Research

HE4 level in ascites may assess the ovarian cancer chemotherapeutic effect

Research

MR findings of primary ovarian granulosa cell tumor with focus on the differentiation with other ovarian sex cord-stromal tumors

Research

Protective role of Ficus deltoidea against BPA-induced impairments of the follicular development, estrous cycle, gonadotropin and sex steroid hormones level of prepubertal rats

Research

Mitochondrial membrane depolarization enhances TRAIL-induced cell death in adult human granulosa tumor cells, KGN, through inhibition of BIRC5

Research

DHEA-induced ovarian hyperfibrosis is mediated by TGF-β signaling pathway